IP Library Granted Patent US 8,697,665
Granted Patent B2
US 8,697,665 · App. 13/121,532 · Granted Apr 15, 2014

Porphobilinogen deaminase gene therapy

Inventors: Antonio Fontanellas Romá (Pamplona Navarra, ES); Gloria González Aseguinolaza (Pamplona Navarra, ES); Maria Sol Rodriguez Pena (Le Mont-sur-Lausanne, CH); Maria Astrid Pañeda Rodriguez (Pamplona Navarra, ES); Jaap Twisk (Amsterdam, NL); Jesús Maria Prieto Valtueña (Pamplona Navarra, ES); Harald Petry (Amsterdam, NL); Sander Jan Hendrik Van Deventer (Amsterdam, NL)
Assignees: Proyecto de Biomedicina CIMA S.L.; Uniqure Biopharma B.V.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,697,665
App. No.
13/121,532
Granted
Apr 15, 2014
Kind
B2
Abstract

The present invention relates to nucleotide sequences coding for human porphobilinogen deaminase that are optimised for higher expression in mammalian cells. The invention further relates to DNA constructs comprising such optimised synthetic coding sequences for use in gene therapy of conditions caused by a deficiency in porphobilinogen deaminase, such as acute intermittent porphyria. Accordingly, the present invention relates to a nucleic acid or a nucleic acid construct comprising a nucleotide sequence coding for a human porphobilinogen deaminase, wherein at least 320 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 1 or wherein at least 305 of the codons coding for the human porphobilinogen deaminase are identical to the codons in SEQ ID NO: 3.

Claims (8)

1. A method for treating a mammalian subject with acute intermittent porphyria, said method comprising intravenously administering to a mammalian subject in need thereof an effective amount of adeno-associated virus (AAV) virions that comprise:

(a) a nucleic acid construct comprising the nucleotide sequence as set forth in SEQ ID NO:1 that encodes human porphobilinogen deaminase (PBGD) protein, operably linked to an α1-anti-trypsin (AAT) promoter combined with a mouse albumin gene enhancer (Ealb) element, and AAV serotype 2 inverted terminal repeats (ITRs); and

(b) capsid proteins from AAV serotypes 1, 2, 5 or 8;

wherein said administration results in expression of the human PBGD protein in the liver of said mammal.

2. The method of claim 1 , wherein said AAV virions are administered as a pharmaceutical composition that further comprises a pharmaceutically acceptable carrier.

3. The method of claim 1 , wherein the promoter-enhancer element combination consists of the nucleotide sequence as set forth in SEQ ID NO: 5.

4. The method of claim 2 , wherein the promoter-enhancer element combination consists of the nucleotide sequence as set forth in SEQ ID NO: 5.

5. The method of claim 4 , wherein the subject is a human.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2014
From: UNIQURE BIOPHARMA B.V.
To: UNIQURE IP B.V.
Reel/Frame 032448/0369 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2014
From: FONTANELLAS ROMA, ANTONIO; GONZALEZ ASEGUINOLAZA, GLORIA; RODRIGUEZ PENA, MARIA SOL; PANEDA RODRIGUEZ, MARIA ASTRID; TWISK, JAAP; PRIETO VALTUENA, JESUS MARIA; PETRY, HARALD; VAN DEVENTER, SANDER JAN HENDRIK
To: AMSTERDAM MOLECULAR THERAPEUTICS (AMT) B.V.; PROYECTO DE BIOMEDICINA CIMA S.L.
Reel/Frame 032145/0828 →
CHANGE OF NAME Recorded Feb 5, 2014
From: AMSTERDAM MOLECULAR THERAPEUTICS (AMT) B.V.
To: UNIQURE BIOPHARMA B.V.
Reel/Frame 032146/0137 →
Priority Claims (1)
EP 08165393 · Sep 29, 2008 · regional
Continuity (2)
Provisional Application 61100881 · Sep 29, 2008
Related Publication 20110262399A1 · Oct 27, 2011